About Us
H3 Biomedicine, the U.S.-based precision oncology research and development subsidiary of Eisai Co., Ltd., is focused on advancing drugs from bench to bedside. Uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics, H3 Biomedicine is developing a pipeline of highly targeted medicines that have the potential to impact the future of cancer care and treatment.
Learn MoreScientific Approach
Unlocking cancer genomics, real-world patient data, and biomarkers in clinical research to deliver on the promise of precision oncology medicine.
Patients
Our core mission at H3 is to accelerate the discovery and clinical development of precision oncology therapeutics for cancer patients and their families.
Find Out More